“Stable Clear-Almost Clear Response Is Sustained up to 3 Years in Patients With Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s599. https://doi.org/10.25251/y4a30r91.